Regeneron Pharmaceuticals (NQ: REGN )
820.00 +17.84 (+2.22%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
All News about Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
March 24, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met...
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
March 24, 2023
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial...
This Is What Whales Are Betting On Regeneron Pharmaceuticals
March 23, 2023
Where Regeneron Pharmaceuticals Stands With Analysts
March 09, 2023
How Is The Market Feeling About Regeneron Pharmaceuticals?
March 07, 2023
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had...
Via Talk Markets
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
March 14, 2023
$250,000 top award goes to Neel Moudgal in the nation’s oldest and most prestigious science and math competition for high school seniors
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following